Ticker Launch
Sign inTry it free

Reverse merger · Completed · TRML

Tourmaline Bio, Inc.

Reverse merger with Talaris Therapeutics, Inc.

Tourmaline Bio, Inc. merged into Talaris Therapeutics, Inc., a Nasdaq-listed clinical-stage biotech that paid a special cash dividend before the merger, in a reverse merger that takes the private company public. The deal was announced on Jun 22, 2023 and closed on Oct 19, 2023. The combined company trades as Tourmaline Bio, Inc. (TRML) on Nasdaq.

Tourmaline Bio, Inc. is a clinical-stage biotechnology company advancing TOUR006, an anti-IL-6 antibody, for thyroid eye disease, atherosclerotic cardiovascular disease and other diseases.

Status
Completed
Private company
Tourmaline Bio, Inc.
Public company
Talaris Therapeutics, Inc.
Public company business before
Nasdaq-listed clinical-stage biotech that paid a special cash dividend before the merger
Announced
Jun 22, 2023
Closed
Oct 19, 2023
Combined company
Tourmaline Bio, Inc. (TRML)
Exchange
Nasdaq
Sector
Biotech & pharma

More on this deal for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other completed reverse mergers